Novel peptomimetics for cardio-protection

  • Category: Pharma
  • Investment Status: IIA Grant
  • Medical Field: Cardio-Vascular
  • Patent Status: provisional
  • Development Status: in vitro and in vivo results
  • Medical Center: Felsenstein Medical Research Center, Rabin Medical Center
  • Inventors: Prof. Edith Hochhauser

We have developed LT87, a novel, patented, non-toxic, cardio-protective peptidomimetic candidate that ameliorated myocardial infraction (MI) .

We investigated the ability of the synthetized peptidomimetics to reduce both hypoxic and septic-like cardio-damage in vitro and in vivo. In both cardiac damage models our novel peptidomimetics showed very promising biological results.

Summary of main in vivo results:

  • The survival rate, measured at 24 hours following MI in the treated group was 100% compared to  58% of the controls subjected to MI .
  • The Infarct size was significantly smaller following 7 days in the treated group.
  • Enzymes leakage at 7 days following MI (CK LDH and Troponin) was significantly lower in the LT 87 treated group when compared to the controls.